Zynex (NASDAQ:ZYXI), a medical technology company specializing in non-opioid pain management devices, issued its second quarter 2025 results on July 31, 2025. The release highligh ...

The treatment, pembrolizumab, is an immunotherapy drug and can slow down cancer growth and improve survival rates, according to health officials ...

More than 3,000 preterm babies in the Ashanti Region have undergone screening to detect Retinopathy of Prematurity (ROP), an ...